Clinical Development
Increasing your chances of success
Over the past decade, early phase clinical development has evolved towards an intensive, knowledge-driven process, stimulated by the need to reduce attrition rates and to increase the chance of success in the expensive late stage of development. For many years, Kinesis Pharma has been a recognized leader for the provision of clinical pharmacology and translational expertise, as a partner for (innovative) pharmaceutical companies. With the involvement of well trained, very experienced experts, a large number of innovative early phase clinical development plans, protocols and reports have been delivered, and subsequently approved by regulatory authorities or acknowledged in due diligence processes.
Key achievements
- Clinical responsibility of the drug development program delegated to Kinesis
- Contribution to timely delivery of data, interim evaluations, reports and required documentation for an Investigational New Drug Application (IND) submission
- Timely delivery of clinical development plans (early phase), including expert validation and decision analysis for various indications
- Preferred provider for pharmacokinetic analysis for over 100 clients, including 3 of the top 10 big pharma companies.
"Early phase clinical development is an intensive knowledge driven process"
Contact details
Edwin Spaans, Pharm.D., |
|